Australia's largest stock trading and investment forum Australia's #1 stock forum

CKA

2.60%

7.9¢ cokal limited

I agree 100% Pump job, nothing more here by the "Top 20"

First 12 Last

Share
Profile

Follow
coeus12345

464 Posts.

176

02/08/24

15:44

Post #: 75047602
Share

Originally posted by home1: ↑

SJ

FFS there is nothing you could of learnt at the meeting that would be relevant to increasing the SP or for that matter that hasn't already been released to the market.

I doubt Dom is that stupid to tell a minority of shareholders anything of importance that hasn't been released to all shareholders .

Your post gives the impression of insider trading.

Suggest you delete it and reword.

Expand

I agree 100%

Pump job, nothing more here by the "Top 20"

CKA Price at posting: 9.5¢ Sentiment: None Disclosure: Held
2 Upvote

0 Great analysis

Reply

Top Stories

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

BCI

BCI reaches close of funding facility for salt-first part of Mardie project

SLS

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

BUX

Buxton projects new graphite province discovery at WA Narryer play

CKA

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

WCN

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

NTI

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

There are more pages in this discussion • 82 more messages in this thread...

First 12 Last

Add CKA (ASX) to my watchlist

(20min delay)
Last 7.9¢		Change 0.002(2.60%)		Mkt cap ! $85.23M

Open	High	Low	Value	Volume
8.1¢	8.1¢	7.6¢	$13.40K	174.6K

Buyers (Bids)

No.	Vol.	Price($)
1	19503	7.7¢

Sellers (Offers)

Price($)	Vol.	No.
8.0¢	238455	1

View Market Depth

No.	Vol.	Price($)
1	19503	0.077
2	17130	0.076
2	267000	0.071
2	147700	0.070
1	25000	0.069

Price($)	Vol.	No.
0.081	112804	1
0.082	150000	2
0.083	40000	1
0.084	394999	2
0.085	102083	2

Last trade - 16.10pm 04/10/2024 (20 minute delay)

CKA (ASX) Chart

I agree 100% Pump job, nothing more here by the "Top 20"

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

BCI reaches close of funding facility for salt-first part of Mardie project

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

Buxton projects new graphite province discovery at WA Narryer play

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

I agree 100% Pump job, nothing more here by the "Top 20"

Top Stories

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

BCI reaches close of funding facility for salt-first part of Mardie project

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

Buxton projects new graphite province discovery at WA Narryer play

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News